Arcus Biosciences Inc Stock Research

Market Summary

USD20.54+0.28

Market Closed

1.38%

RCUS Alerts

Big jump in Revenue (Y/Y)
Losses in recent quarter

RCUS Stock Price

RCUS RSI Chart

RCUS Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-5.38

Price/Sales (Trailing)

12.62

EV/EBITDA

-4.67

Price/Free Cashflow

-4.69

RCUS Price/Sales (Trailing)

RCUS Profitability

EBT Margin

-237.50%

Return on Equity

-40.64%

Return on Assets

-19.85%

Free Cashflow Yield

-21.33%

RCUS Fundamentals

RCUS Revenue

Revenue (TTM)

119.0M

Revenue Y/Y

38.85%

Revenue Q/Q

-25.72%

RCUS Earnings

Earnings (TTM)

-279.0M

Earnings Y/Y

-17.66%

Earnings Q/Q

-18.6%

Price Action

52 Week Range

15.7036.13

(Low)(High)

Last 7 days

13.8%

Last 30 days

11.4%

Last 90 days

16.9%

Trailing 12 Months

8.4%

RCUS Financial Health

Current Ratio

5.53

RCUS Investor Care

Shares Dilution (1Y)

2.06%

Peers (Alternatives to Arcus Biosciences)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	117.9B	26.2B	-7.64%	-12.03%	14.89	4.5	-0.48%	38.34%
GILD	96.0B	27.0B	-5.50%	23.66%	17.2	3.55	-1.56%	23.65%
MRNA	49.0B	15.1B	-4.27%	-12.12%	10.25	3.26	-33.37%	-67.32%
BIIB	42.8B	10.1B	-4.73%	48.21%	13.67	4.24	-6.61%	115.98%
MID-CAP
NBIX	8.7B	1.6B	-13.93%	-4.24%	136.39	5.46	32.38%	-10.36%
DNLI	4.1B	-	17.13%	24.41%	-11.15	38.1	122.90%	-29.67%
BEAM	2.4B	76.7M	3.81%	-9.32%	-7.51	30.96	41.73%	-32.75%
BBIO	2.2B	107.9M	-4.32%	100.88%	-4.54	20.39	54.84%	17.36%
SMALL-CAP
RCUS	1.5B	119.0M	11.39%	8.39%	-5.38	12.62	-69.61%	-584.39%
REPL	1.1B	10.0M	8.51%	30.70%	-6.18	107.56	215.65%	-47.65%
NVAX	694.6M	-	4.27%	-85.45%	-0.6	0.35	72.89%	12.32%
FATE	495.9M	136.9M	-20.60%	-78.14%	-2.11	3.62	116.83%	-0.93%
SGMO	186.8M	241.0M	-25.83%	-69.32%	-1.47	0.78	113.96%	27.87%
VXRT	165.4M	697.0K	50.34%	-66.48%	-1.53	237.34	47.98%	-35.48%
IBIO	8.7M	-	-35.78%	-88.38%	-0.11	3.21	0.51%	-129.47%

Financials for Arcus Biosciences

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	6.2%	119	112	433	409	392
Operating Expenses	6.6%	418	392	358	342	332
S&GA Expenses	5.8%	110	104	99.00	89.00	80.00
R&D Expenses	6.9%	308	288	258	253	252
EBITDA	-392.3%	-260	89.00	75.00	-281	-
EBITDA Margin	-1230.1%	-2.32*	0.21*	0.18*	-0.72*	-
Earnings Before Taxes	-4.1%	-277	-266	83.00	70.00	61.00
EBT Margin	-1338.9%	-2.37*	0.19*	0.17*	-0.73*	-
Net Income	-4.5%	-279	-267	80.00	67.00	58.00
Net Income Margin	-1390.3%	-2.38*	0.18*	0.16*	0.15*	-
Free Cahsflow	0.1%	432	432	452	439	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-6.8%	1,254	1,345	1,394	1,477	1,543
Current Assets	-4.9%	1,015	1,067	1,101	1,227	1,264
Cash Equivalents	15.5%	238	206	218	273	549
Net PPE	5.7%	37.00	35.00	34.00	33.00	33.00
Liabilities	-4.7%	695	729	747	-	-
Current Liabilities	-7.3%	179	193	177	164	161
Shareholder's Equity	-8.7%	600	657	699	747	797
Retained Earnings	-14.8%	-622	-542	-474	-409	-343
Additional Paid-In Capital	1.6%	1,183	1,165	1,145	-	-
Shares Outstanding	0.3%	73.00	73.00	72.00	72.00	72.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-171.7%	-314	438	446	473	464
Share Based Compensation	3.8%	67.00	65.00	63.00	61.00	59.00
Cashflow From Investing	96.1%	-15.94	-413	-441	-553	-334
Cashflow From Financing	-42.2%	19.00	33.00	33.00	32.00	30.00

Risks for RCUS

What is the probability of a big loss on RCUS?

100%

Probability that Arcus Biosciences stock will be more than 20% underwater in next one year

100%

Probability that Arcus Biosciences stock will be more than 30% underwater in next one year.

88.5%

Probability that Arcus Biosciences stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RCUS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcus Biosciences was unfortunately bought at previous high price.

Drawdowns

Returns for RCUS

Cumulative Returns on RCUS

5.8%

5-Year Cumulative Returns

-13.1%

3-Year Cumulative Returns

What are the long-term rolling returns for RCUS?

FIve years rolling returns for Arcus Biosciences.

Annualized Returns

Which funds bought or sold RCUS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-23	Capital Impact Advisors, LLC	added	26.89	39,811	373,938	0.46%
2023-05-22	PUTNAM INVESTMENTS LLC	sold off	-100	-2,722,130	-	-%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-4.44	-664,562	3,557,440	-%
2023-05-19	Coppell Advisory Solutions LLC	sold off	-100	-4,136	-	-%
2023-05-18	JPMORGAN CHASE & CO	added	4.87	-798,000	9,850,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-5.39	-179,000	902,000	-%
2023-05-17	VIRGINIA RETIREMENT SYSTEMS ET AL	added	23.38	-25,904	1,025,730	0.01%
2023-05-17	Thrivent Financial for Lutherans	reduced	-3.39	-164,000	942,000	-%
2023-05-16	Hudson Bay Capital Management LP	added	359	3,153,900	4,187,900	0.02%
2023-05-16	Kiwi Wealth Investments Limited Partnership	unchanged	-	-135,198	1,010,660	0.07%

Latest Funds Activity

Are funds buying RCUS calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own RCUS

No. of Funds

Arcus Biosciences News

Schedule 13G FIlings of Arcus Biosciences

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	biotechnology value fund l p	1.7%	1,236,002	SC 13G/A
Feb 14, 2023	pfm health sciences, lp	3.7%	6	SC 13G/A
Feb 09, 2023	vanguard group inc	6.04%	4,373,177	SC 13G
Jan 26, 2023	blackrock inc.	13.0%	9,389,048	SC 13G/A
Jan 20, 2023	blackrock inc.	13.0%	9,389,048	SC 13G/A
Oct 17, 2022	pfm health sciences, lp	5.5%	6	SC 13G
May 09, 2022	blackrock inc.	11.1%	7,967,677	SC 13G
Mar 14, 2022	biotechnology value fund l p	3.0%	2,156,510	SC 13G
Feb 14, 2022	ecor1 capital, llc	7.9%	5,523,358	SC 13G/A
Feb 14, 2022	pfm health sciences, lp	4.9%	6	SC 13G/A

RCUS Fair Value

Show Fair-Value

Recent SEC filings of Arcus Biosciences

View All Filings

Date Filed	Form Type	Document
May 15, 2023	8-K	Current Report
May 09, 2023	8-K	Current Report
May 09, 2023	10-Q	Quarterly Report
Apr 25, 2023	ARS	ARS
Apr 21, 2023	DEFA14A	DEFA14A
Apr 21, 2023	DEF 14A	DEF 14A
Mar 20, 2023	4	Insider Trading
Mar 10, 2023	8-K	Current Report
Mar 10, 2023	3	Insider Trading
Feb 28, 2023	S-8	Employee Benefits Plan

Latest Insider Trading transactions for RCUS

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-16	Jarrett Jennifer	sold	-146,734	16.81	-8,729	chief operating officer
2023-01-27	Jarrett Jennifer	sold	-37,632	23.52	-1,600	chief operating officer
2023-01-26	Jarrett Jennifer	sold	-7,068	23.56	-300	chief operating officer
2023-01-23	ROSEN TERRY J	acquired	-	-	105,700	chief executive officer
2023-01-23	Nuyten Dimitry SA	acquired	-	-	34,000	chief medical officer
2023-01-23	Goeltz II Robert C.	acquired	-	-	34,000	chief financial officer
2023-01-23	Jarrett Jennifer	acquired	-	-	45,800	chief operating officer
2023-01-23	Jaen Juan C.	acquired	-	-	45,800	president
2023-01-23	Tang Carolyn C.	acquired	-	-	34,000	general counsel
2022-12-16	Jaen Juan C.	sold	-136,407	30.7501	-4,436	president

About Arcus Biosciences

Terry J. Rosen

www.arcusbio.com

370

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Income Statement

2023-03-31

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Total revenues	$ 25	$ 18
Operating expenses:
Research and development (Net of recoveries of $33 and $30 from a related party)	81	61
General and administrative	30	24
Total operating expenses	111	85
Loss from operations	(86)	(67)
Non-operating income (expense):
Interest and other income, net	9
Effective interest on liability for sale of future royalties	(1)
Total non-operating income, net	8
Loss before income taxes	(78)	(67)
Income tax expense	(2)	(1)
Net loss	$ (80)	$ (68)
Net loss per share, basic	$ (1.09)	$ (0.96)
Net loss per share, diluted	$ (1.09)	$ (0.96)
Shares used to compute net income loss per share, basic	73.0	71.2
Shares used to compute net income loss per share, diluted	73.0	71.2
License and Development Services Revenue
Revenues:
Total revenues	$ 17	$ 8
Other Collaboration Revenue
Revenues:
Total revenues	$ 8	$ 10

RCUS Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 238	$ 206
Marketable securities	716	803
Receivable from collaboration partners ($33 and $39 from a related party)	33	39
Prepaid expenses and other current assets	28	19
Total current assets	1,015	1,067
Long-term marketable securities	90	129
Property and equipment, net	37	35
Other noncurrent assets ($3 and $2 from a related party)	112	114
Total assets	1,254	1,345
Current liabilities:
Accounts payable	28	20
Deferred revenue ($97 and $97 to a related party)	97	97
Other current liabilities	54	76
Total current liabilities	179	193
Deferred revenue, noncurrent ($330 and $355 to a related party)	330	355
Other noncurrent liabilities	145	140
Commitments
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding	0	0
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 73.1 shares in 2023 and 72.9 shares in 2022 issued and outstanding	1,226	1,206
Accumulated deficit	(622)	(542)
Accumulated other comprehensive loss	(4)	(7)
Total stockholders’ equity	600	657
Total liabilities and stockholders’ equity	$ 1,254	$ 1,345